🧬Tidera Health
⚕️

Educational tool only. Does not confirm eligibility or provide medical advice. Always consult your physician before pursuing any trial.

NeurologyICD-10: G36.0

Find Recruiting Clinical Trials for Neuromyelitis Optica (NMOSD)

Search AQP4-IgG positive, MOG-antibody, and seronegative NMOSD trials — relapse prevention and novel biologic studies.

🔍 Search Neuromyelitis Optica Trials →

About Neuromyelitis Optica

Neuromyelitis optica spectrum disorder (NMOSD) is a rare, severe autoimmune disease of the central nervous system causing attacks of optic neuritis (vision loss) and transverse myelitis (paralysis, sensory loss, bladder dysfunction), with potential brainstem involvement. It is predominantly associated with autoantibodies against aquaporin-4 (AQP4-IgG, ~75% of patients), with a distinct MOG-antibody-associated disease (MOGAD) representing a separate entity (~25%). Unlike MS, NMOSD does not respond to MS disease-modifying therapies and can worsen with some of them. Three targeted therapies are now FDA-approved for AQP4-IgG positive NMOSD: eculizumab, inebilizumab, and satralizumab.

What Types of Neuromyelitis Optica Clinical Trials Exist?

NMOSD trials are focused on AQP4-IgG positive and MOG-antibody associated disease. For AQP4-positive NMOSD: next-generation complement inhibitors, FcRn inhibitors (to reduce AQP4-IgG), and combination prevention strategies. For MOGAD: dedicated trials are now launching after the field was previously treated as NMOSD. B-cell depleting agents, tocilizumab (IL-6 inhibitor), and novel immunosuppressants are in development. AQP4-IgG status, MOGAD testing, annualized relapse rate, and prior therapy are critical eligibility factors.

Find Recruiting Neuromyelitis Optica Trials Near You

Enter your profile and we'll search ClinicalTrials.gov in real time — matching trials to your age, location, and treatment history. Free, no account required.

Search Neuromyelitis Optica Trials →

Data from ClinicalTrials.gov · Updated in real time · Educational use only

Frequently Asked Questions

What clinical trials are available for NMOSD?▾
Recruiting NMOSD trials include next-generation complement inhibitors, FcRn inhibitors for AQP4-positive NMOSD, dedicated MOG-antibody disease (MOGAD) trials (now separated from AQP4-NMOSD in trial design), IL-6 inhibitor studies, and neuroprotection/remyelination trials for residual disability.
How does AQP4-IgG vs. MOG-antibody status affect NMOSD trial eligibility?▾
AQP4-IgG positive and MOG-antibody positive NMOSD are now treated as distinct diseases in clinical trial design. AQP4-positive trials enroll patients with confirmed AQP4-IgG seropositivity. MOG-antibody disease trials require confirmed MOG-IgG antibodies. Seronegative NMOSD (negative for both) has limited targeted options but may qualify for symptom management or neuroprotection trials.
Can I join an NMOSD trial if I am already on an approved therapy?▾
Some NMOSD trials allow continuation of current FDA-approved therapies (eculizumab, inebilizumab, satralizumab) and test add-on or neuroprotection approaches. Others test alternatives to current therapies for patients with breakthrough disease or intolerance. Always consult your neurologist before considering any change to NMOSD preventive therapy, as untreated attacks can cause irreversible disability.

Related Conditions

Multiple SclerosisMyasthenia GravisLupus (SLE)

Data source: All clinical trial information is sourced from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Tidera Health is an independent educational platform and is not affiliated with ClinicalTrials.gov or the National Library of Medicine. Always verify trial details directly with the research coordinator or your physician.